Keywords

• N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
• ZD1839
• 4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline

Quick Details

• ProName: Gefitinib
• CasNo: 184475-35-2
• Molecular Formula: C22H24ClFN4O3
• Appearance: White to Light yellow powder to crysta...
• Application: Gefitinib is a potent epidermal growth...
• ProductionCapacity: /
• Purity: 98
• Storage: Store at RT
• LimitNum: 0
• density: 1.3±0.1 g/cm3
• boiling point: 586.8±50.0 °C at 760 mmHg
• melting point: 119-1200C
• molecular weight : 446.902
• flash point : 308.7±30.1 °C
• Precise mass: 446.152100
• PSA: 68.74000
• LogP: 4.11

Superiority

Jilin Tianyun New Materials Co., Ltd. is a professional production enterprise that production, processing, and export, mainly engaged in various organic chemicals. The company has a wealth of professional experience, reliable product quality, reasonable prices, and products are exported to countries around the world, which can meet your diverse needs. In our business cooperation with clients, we always adhere to the principle of equality and mutual benefit, and are deeply trusted and recognized by our clients. If you are interested in our company and our products, please feel free to visit our website or contact us directly for more information.We look forward to establishing a long-term stable and win-win business relationship with you.

Details

Gefitinib effects

(1) Compete for the Mg-ATP binding site on the catalytic region of EGFR-TK and block its signal transduction;
(2) inhibit the activation of mitogen-activated protein kinases and promote apoptosis;

(3) Inhibition of tumor angiogenesis. Iressa was approved by the Ministry of Health and Welfare of Japan for the treatment of advanced NSCLC on July 5, 2002, and was approved by the FDA as a third-line treatment for NSCLC on May 5, 2003, with a recommended dose of 250 mg, PO, qd.
It is worth mentioning that the FDA's decision was approved when Iressa had just completed a Phase II clinical trial and the Phase III clinical trial had not yet been completed. In 2003, the Lung Cancer Committee of the Chinese Anti-Cancer Association proposed in the treatment guidelines for inoperable NSCLC: Iressa is recommended for the treatment of patients with locally advanced or distant metastasis of non-small cell lung cancer with platinum-containing regimen and Docetaxel chemotherapy failure. [3]